DDrare: Database of Drug Development for Rare Diseases

283. 後天性赤芽球癆
［臨床試験数：17，薬物数：36（DrugBank：19），標的遺伝子数：16，標的パスウェイ数：91］

Searched query = "Acquired pure red cell aplasia", "Pure red cell aplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AF37702 Injection; AF37702, Hematide; Alemtuzumab; Anti-thymocyte globulin; Bortezomib; Bortezomib/dexamethasone; Campath; Campath, Chemo and/or TBI Allo SCT; Cyclophosphamide; Cyclophosphamide + pred; Cyclosporine; Cyclosporine A; Cyclosporine combine with mycophenolate mofetil; Daclizumab; Dexamethasone; Filgrastim; Fludarabine; Fludarabine Phosphate; Hematide; Hematide, peginesatide; Leucine; Methylprednisolone; Mycophenolate; Mycophenolate mofetil; Other: Laboratory Biomarker Analysis; Peginesatide; Phosphate; Prednisone; Procedure: Autologous Peripheral Blood Stem Cell Transplantation; Procedure: Peripheral Blood Stem Cell Transplantation; Radiation: Total Body Irradiation; Radiation: Total-Body Irradiation; Rituximab; Sirolimus; Tacrolimus; Trifluoperazine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04423367 (ClinicalTrials.gov)	September 13, 2020	5/6/2020	Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment	Safety and Efficacy of Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment: A Prospective Phase II Trial	Acquired Pure Red Cell Aplasia	Drug: bortezomib /dexamethasone	Institute of Hematology & Blood Diseases Hospital	NULL	Recruiting	18 Years	70 Years	All	17	Phase 2	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04423367
(ClinicalTrials.gov)

September 13, 2020

5/6/2020

Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment

Safety and Efficacy of Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment: A Prospective Phase II Trial

Acquired Pure Red Cell Aplasia

Drug: bortezomib /dexamethasone

Institute of Hematology & Blood Diseases Hospital

NULL

Recruiting

18 Years

70 Years

All

Phase 2

China